1. Home
  2. IFRX vs BRFH Comparison

IFRX vs BRFH Comparison

Compare IFRX & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • BRFH
  • Stock Information
  • Founded
  • IFRX 2007
  • BRFH 2005
  • Country
  • IFRX Germany
  • BRFH United States
  • Employees
  • IFRX N/A
  • BRFH N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • BRFH Packaged Foods
  • Sector
  • IFRX Health Care
  • BRFH Consumer Staples
  • Exchange
  • IFRX Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • IFRX 53.5M
  • BRFH 46.2M
  • IPO Year
  • IFRX 2017
  • BRFH N/A
  • Fundamental
  • Price
  • IFRX $1.60
  • BRFH $3.01
  • Analyst Decision
  • IFRX Strong Buy
  • BRFH
  • Analyst Count
  • IFRX 4
  • BRFH 0
  • Target Price
  • IFRX $7.75
  • BRFH N/A
  • AVG Volume (30 Days)
  • IFRX 577.2K
  • BRFH 5.4K
  • Earning Date
  • IFRX 08-07-2025
  • BRFH 08-13-2025
  • Dividend Yield
  • IFRX N/A
  • BRFH N/A
  • EPS Growth
  • IFRX N/A
  • BRFH N/A
  • EPS
  • IFRX N/A
  • BRFH N/A
  • Revenue
  • IFRX $191,224.00
  • BRFH $10,979,000.00
  • Revenue This Year
  • IFRX N/A
  • BRFH $23.09
  • Revenue Next Year
  • IFRX $1,336.36
  • BRFH $41.03
  • P/E Ratio
  • IFRX N/A
  • BRFH N/A
  • Revenue Growth
  • IFRX 54.36
  • BRFH 24.51
  • 52 Week Low
  • IFRX $0.71
  • BRFH $1.81
  • 52 Week High
  • IFRX $2.82
  • BRFH $4.60
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 89.35
  • BRFH 51.79
  • Support Level
  • IFRX $0.82
  • BRFH $2.87
  • Resistance Level
  • IFRX $0.96
  • BRFH $3.50
  • Average True Range (ATR)
  • IFRX 0.11
  • BRFH 0.19
  • MACD
  • IFRX 0.06
  • BRFH 0.04
  • Stochastic Oscillator
  • IFRX 100.00
  • BRFH 51.01

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: